INHIBRX BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INHIBRX BIOSCIENCES, INC. (INBX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.10M, a 12.06% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.65M, a 8.29% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.17M, a 7.08% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.77M, a 94.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.14M, a 80.97% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $58.52M, a 135.52% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $24.85M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.10M 10-Q · filed 2026-08-13 | $5.76M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $2.65M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $11.14M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $3.17M 10-Q · filed 2025-11-14 | $5.95M derived: sum of 2 quarters · filed 2026-08-13 | $8.39M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $2.77M 10-Q · filed 2026-08-13 | $5.22M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $2.45M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $58.52M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $2.96M 10-Q · filed 2025-11-14 | $49.14M derived: sum of 2 quarters · filed 2025-11-14 | $55.54M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $46.17M 10-Q · filed 2025-11-14 | $52.57M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $6.40M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $24.85M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $6.53M 10-Q · filed 2024-11-14 | $12.78M derived: sum of 2 quarters · filed 2024-11-14 | $18.42M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $6.25M 10-Q · filed 2024-11-14 | $11.89M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $5.64M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |